自体免疫疾病体外诊断及实验室自建市场（依检测类型、技术、产品类型、最终用户、应用及样本类型划分）－2025-2032年全球预测

预计到 2032 年，自体免疫疾病的体外诊断和实验室自建检测市场将成长至 275.6 亿美元，复合年增长率为 5.25%。

本文简要说明了当前自体免疫免疫诊断领域，包括检测方法创新、临床应用驱动因素以及对相关人员的策略意义。

诊断创新、不断演进的临床路径以及临床医生对自体免疫疾病检测准确性日益增长的需求，共同为诊断和检测服务相关人员创造了一个关键时刻。本执行摘要概述了影响诊断工作流程和病人历程的检测平台最新进展、临床医生的应用模式以及体外诊断和实验室自建检测之间的相互作用。重点在于技术选择、监管政策调整和实验室运作模式如何影响检测方法的选择、分析性能以及后续的医疗协调。

诊断团队和实验室负责人在评估下一代检测方法的应用时，必须权衡分析灵敏度和特异性与工作流程整合及报销的实际情况。实验室主任越来越重视那些既能缩短週转时间又能保持临床可靠性的检测方法，而临床医生则在寻求能够支持更快、更明确诊断的检测手段。同时，製造商正在完善产品系列，以满足血清学和生物标记检测领域尚未满足的需求，而学术中心则在拓展转化医学项目，以检验新的目标。

综上所述，这些动态凸显了产品开发、临床检验和商业化策略协调一致的重要性。本摘要概述了领导者在製定循证医学方案、优化实验室运营以及与支付方和临床医生合作以提高诊断有效性和改善患者预后时应重点关注的战略考虑因素。

检测方法创新、监管动态和临床工作流程现代化如何再形成自体免疫诊断并加速跨领域合作

近期的创新趋势正在改变自体免疫疾病诊断的开发、检验和临床应用方式。检测化学和平台整合技术的进步提高了分析精度，而多重检测能力则使得从单一样本中进行广泛的免疫分析成为可能。同时，实验室正在积极采用自动化和数位化连接技术，以简化工作流程并支援高通量检测。

监管和报销环境也在不断变化，迫使製造商和实验室加快进行强有力的临床检验并累积真实世界证据。这一趋势有利于那些展现出实际临床效用并能融入临床医师决策流程的检测方法。实验室自建检测（LDT）与市售体外诊断试剂（IVD）的兴起正在建构一个互补的生态系统：LDT通常能够快速满足特定或新兴的临床需求，而市售IVD则优先考虑标准化和扩充性。因此，临床实验室、学术研究中心和商业製造商之间的策略伙伴关係日益普遍，从而促进了生物标记向已验证检测方案的快速转换。

此外，以病人为中心的照护模式以及临床医师对自体免疫异质性的认识不断提高，凸显了对更精准诊断演算法的需求。因此，相关人员增加对临床医生教育、多学科诊断通讯协定以及将血清学结果与临床表型联繫起来的综合报告的投入。总体而言，这种转变正在推动自体免疫诊断朝着更协作、数据主导的方向发展，其中技术能力、证据生成和营运准备相互交织，共同决定着临床应用。

评估2025年关税调整对诊断供应链、筹资策略和区域製造决策的累积营运影响

2025年关税政策调整及相关贸易措施为诊断剂和仪器组件的全球供应链引入了新的变数。这些关税调整增加了製造商和实验室采购的复杂性，促使他们重新评估筹资策略、库存管理和供应商多元化。为此，许多相关人员探索了近岸外包方案和替代供应商关係，以降低进口成本波动和前置作业时间不确定性的风险。

为因应关税变化，供应链做出了相应调整，促使製造商重新思考材料清单窗口，增加了关键耗材的缓衝库存，并儘可能与全国或区域经销商签订长期合约。这些营运调整强调了供应链的透明度和主动的供应商风险评估，同时确保了检测的连续性。

此外，关税环境促使各方就生产布局和区域生产能力展开策略对话。一些公司加快了对区域製造和最终组装能力的投资，以降低跨境风险；而另一些公司则专注于检验多家试剂供应商，以确保供应的连续性。总而言之，这些调整凸显了贸易政策与诊断项目韧性之间的重要联繫，并强调了情境规划和灵活采购方式对于维持检测和实验室运作的必要性。

详细的细分洞察揭示了测试类型、检测技术、产品类型、最终用户、临床应用和样本方式如何影响策略选择。

细分市场分析揭示了不同检测类型、检测技术、产品类型、最终用户、应用和样本类型之间的差异化动态，这些动态会影响临床效用、采购选择和开发重点。检测类型包括抗环瓜氨酸肽抗体、抗核抗体、乳糜泻和类风湿因子，每种检测类型都有其独特的分析要求以及临床医生对特异性和可解释性的期望。由于抗环瓜氨酸肽抗体具有预后价值，因此通常优先用于类风湿性关节炎的早期诊断。抗核抗体检测通常用作筛检工具，需要相应的演算法来指导预后诊断检测。乳糜泻的血清学检测需要与病历和基因检测流程紧密结合，而类风湿因子检测作为更广泛的发炎检测的一部分仍然具有重要价值。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 采用高灵敏度抗CCP检测方法对类风湿性关节炎患者进行风险分层
• 利用基于次世代定序的实验室自建技术进行修格兰氏症候群的个人化诊断
• 用于即时自体免疫生物标记定量分析的新兴照护现场微流体平台
• 将机器学习演算法扩展到体外诊断工作流程中，以解读复杂的自身抗体光谱。
• 实验室开发的用于系统性红斑狼疮中抗双股DNA抗体和补体蛋白多重检测的检测方法的发展
• 将数位免疫检测与远端医疗平台结合，用于远端监测自体免疫疾病復发
• 为实现自体免疫疾病检测实验室自建检测（LDT）临床检验的标准化，监管机构正努力协调相关规定。
• 基于CRISPR技术的超灵敏检测自体免疫相关基因突变的诊断工具的实现
• 高通量蛋白质体学在体外诊断试剂套件中的应用迅速增长，用于识别自体免疫疾病的新型生物标记
• 生技公司与诊断实验室进行策略合作，共同开发针对自体免疫免疫疾病的实验室自建检测组合。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章自体免疫疾病体外诊断与实验室自建市场（按检测类型划分）

• 抗环瓜氨酸肽
• 抗核抗体
• 乳糜泻
• 类风湿因子

第九章自体免疫疾病体外诊断与实验室自建市场：依技术分类

• 化学冷光免疫检测
• 酵素结合免疫吸附试验
• 萤光免疫分析法
• 多重免疫检测

第十章自体免疫疾病体外诊断与实验室自建市场（依产品类型划分）

• 体外诊断试剂
• 实验室开发测试

第十一章自体免疫疾病体外诊断与实验室自建市场（依最终用户划分）

• 学术研究机构
• 诊断实验室
• 医院检查室
• 参考实验室

第十二章自体免疫疾病体外诊断与实验室自建市场：按应用领域划分

• 乳糜泻
• 多发性硬化症
• 类风湿性关节炎
• 全身性红斑性狼疮
• 1型糖尿病

第十三章自体免疫疾病体外诊断与实验室自建市场（依样本类型划分）

• 干涸的血迹
• 电浆
• 血清
• 全血

第十四章 各地区自体免疫疾病体外诊断及实验室自建市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章自体免疫疾病体外诊断与实验室自建市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国自体免疫疾病体外诊断与实验室自建市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Siemens Healthineers AG
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • DiaSorin SpA
  • Quidel Corporation
  • EUROIMMUN AG

The IVD & LDT For Autoimmune Diseases Market is projected to grow by USD 27.56 billion at a CAGR of 5.25% by 2032.

A concise orientation to the current autoimmune diagnostics environment highlighting assay innovation, clinical adoption drivers, and strategic implications for stakeholders

The convergence of diagnostic innovation, evolving clinical pathways, and growing clinician demand for precision in autoimmune disease detection has created a pivotal moment for stakeholders across diagnostics and laboratory services. This executive summary distills recent advances in assay platforms, clinician adoption patterns, and the interplay between in vitro diagnostics and lab-developed tests that together shape diagnostic workflows and patient journeys. It centers on how technological choices, regulatory clarity, and laboratory operational models influence test selection, analytical performance, and downstream care coordination.

As diagnostics teams and laboratory leaders evaluate next-generation assay adoption, they must balance analytical sensitivity and specificity with workflow integration and reimbursement realities. Laboratory directors increasingly prioritize assays that reduce turnaround time while preserving clinical confidence, and clinicians seek tests that support earlier, more definitive diagnoses. Meanwhile, manufacturers refine product portfolios to address unmet needs in serology and biomarker detection, and academic centers expand translational programs to validate novel targets.

Taken together, these dynamics underscore the importance of aligning product development, clinical validation, and commercialization strategies. This summary outlines the strategic considerations that leaders should weigh when designing evidence generation plans, optimizing laboratory operations, and engaging payers and clinicians to improve diagnostic impact and patient outcomes.

How converging assay innovations, regulatory dynamics, and clinical workflow modernization are reshaping autoimmune diagnostics and accelerating cross-sector collaboration

Recent transformative shifts have altered how autoimmune disease diagnostics are developed, validated, and adopted across clinical settings. Advances in assay chemistries and platform integration have improved analytical precision, while multiplexing capabilities enable broader immunoprofiling from single samples. In parallel, laboratories are embracing automation and digital connectivity to streamline workflows and support high-throughput testing, which in turn affects turnaround times and capacity management.

Regulatory and reimbursement landscapes have also evolved, prompting manufacturers and laboratories to accelerate robust clinical validation and real-world evidence generation. These trends favor tests that demonstrate actionable clinical utility and that fit into clinicians' decision-making pathways. The rise of lab-developed tests alongside commercial in vitro diagnostics has created a complementary ecosystem: LDTs often address niche or emergent clinical needs quickly, while commercial IVDs prioritize standardization and scalability. Consequently, strategic partnerships between clinical laboratories, academic research centers, and commercial manufacturers have grown more common, facilitating faster translation of biomarkers into validated testing options.

Furthermore, patient-centric care models and increased clinician awareness of autoimmune heterogeneity emphasize the need for more precise diagnostic algorithms. As a result, stakeholders are investing in clinician education, multidisciplinary diagnostic protocols, and integrated reporting that links serologic results to clinical phenotypes. Overall, these shifts are driving a more collaborative, data-driven approach to autoimmune diagnostics, where technological capability, evidence generation, and operational readiness intersect to determine clinical adoption.

Assessing the cumulative operational consequences of 2025 tariff adjustments on diagnostic supply chains, sourcing strategies, and regional manufacturing decisions

Tariff policy adjustments and related trade measures introduced in 2025 have introduced new variables into global supply chains for diagnostic reagents and instrument components. These tariff developments increased procurement complexity for manufacturers and laboratories, prompting reassessments of sourcing strategies, inventory management, and supplier diversification. In response, many stakeholders examined nearshoring options and alternative supplier relationships to mitigate exposure to variable import costs and lead-time uncertainties.

Supply chain reactions to tariff changes encouraged manufacturers to revisit bill-of-materials strategies and to prioritize modular instrument designs that allow substitution of nonproprietary parts. Simultaneously, diagnostic laboratories adjusted procurement windows, increasing buffer inventories for critical consumables and negotiating longer-term agreements with domestic or regional distributors when feasible. These operational shifts, while preserving testing continuity, placed a premium on supply chain visibility and proactive supplier risk assessments.

Moreover, the tariff environment catalyzed strategic conversations about manufacturing footprint and regional capacity. Some firms accelerated investments in regional manufacturing and final assembly capabilities to reduce cross-border exposure, while others amplified their focus on validating multiple reagent suppliers to ensure continuity. Collectively, these adaptations underscore the critical link between trade policy and diagnostic program resilience, highlighting the need for scenario planning and agile procurement practices to sustain testing access and laboratory operations.

Detailed segmentation insights revealing how test types, assay technologies, product categories, end users, clinical applications, and sample modalities influence strategic choices

Segmentation analysis reveals differentiated dynamics across test types, technologies, product categories, end users, applications, and sample types that influence clinical utility, procurement choices, and development priorities. Based on Test Type, the landscape includes Anti Cyclic Citrullinated Peptide, Antinuclear Antibody, Celiac Disease, and Rheumatoid Factor, each presenting unique analytical requirements and clinician expectations for specificity and interpretability. Anti Cyclic Citrullinated Peptide assays are commonly prioritized for early rheumatoid arthritis diagnosis because their analytical characteristics support prognostic use, whereas Antinuclear Antibody testing often serves as a screening tool requiring reflex algorithms to guide follow-up testing. Celiac Disease serology necessitates tight integration with clinical history and genetic testing pathways, and Rheumatoid Factor testing retains value as part of broader inflammatory workups.

Based on Technology, stakeholders evaluate platforms including Chemiluminescence Immunoassay, Enzyme Linked Immunosorbent Assay, Fluorescence Immunoassay, and Multiplex Immunoassay when balancing throughput, sensitivity, and cost. Chemiluminescence Immunoassay platforms often appeal to high-volume laboratories seeking automated workflows and consistent performance, while Enzyme Linked Immunosorbent Assay remains a flexible option for lower throughput and centralized reference testing. Fluorescence Immunoassay can offer enhanced sensitivity for specific analytes, and Multiplex Immunoassay enables simultaneous profiling that supports differential diagnosis and research-grade immunophenotyping.

Based on Product Type, distinctions between In Vitro Diagnostic and Lab Developed Test pathways shape validation rigor, regulatory interaction, and commercial strategy. In Vitro Diagnostic solutions emphasize standardized kits and instrument integration to facilitate broad adoption, whereas Lab Developed Tests provide customization and rapid responsiveness to evolving clinical needs, especially in specialized centers. Based on End User, academic and research institutes, diagnostic laboratories, hospital laboratories, and reference laboratories each maintain different priorities related to validation depth, throughput, clinical integration, and payer relationships; academic centers drive translational validation, hospital laboratories focus on clinician alignment and rapid turnaround, and reference laboratories emphasize scale and centralized expertise.

Based on Application, reporting for Celiac Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Type 1 Diabetes demands tailored panels and interpretive frameworks that reflect disease-specific biomarker signatures and clinical algorithms. Clinicians increasingly expect tests to provide context-rich reports that integrate serologic patterns with likelihood assessments and recommended next steps. Finally, based on Sample Type, modalities such as Dried Blood Spot, Plasma, Serum, and Whole Blood affect collection logistics, stability considerations, and suitability for decentralized testing or remote sampling programs. Dried Blood Spot sampling supports outreach and decentralized screening initiatives, while plasma and serum remain predominant for high-sensitivity assays performed in centralized laboratories. These segmentation insights collectively inform product development priorities, clinical validation strategies, and commercialization approaches across the diagnostic ecosystem.

How distinct regulatory environments, payer frameworks, and clinical infrastructures across major regions determine diagnostic adoption patterns and strategic market entry

Regional dynamics shape adoption patterns, regulatory pathways, and commercial approaches in distinctive ways. Across the Americas, health systems vary from highly centralized national programs to mixed public-private models, and payer influence strongly shapes test reimbursement pathways and adoption velocity. Clinical practice guidelines and specialist networks in major markets drive clinician demand for specific autoimmune assays, and academic medical centers often lead translational validation that informs broader clinical adoption. Consequently, engagement strategies that align with local guideline development and payer evidence requirements tend to facilitate uptake.

In Europe, Middle East & Africa, the regulatory environment is heterogeneous, with some regions emphasizing centralized regulatory reviews and others maintaining national approval pathways. This diversity encourages modular regulatory and market entry strategies, alongside targeted clinical studies that address country-specific clinical practice patterns. Additionally, public health priorities and variable laboratory infrastructure across the region influence the feasibility of decentralized testing and the adoption of automated platforms versus reference lab models. Manufacturers and laboratories therefore balance regional evidence generation with flexible distribution partnerships.

Asia-Pacific markets demonstrate rapid uptake of innovative diagnostic technologies, supported by investments in clinical research infrastructures and expanding private laboratory networks. Diverse healthcare financing models and large patient populations create opportunities for both centralized reference testing and point-of-care initiatives, particularly when supported by remote-sampling approaches like Dried Blood Spot. Overall, regional strategies must account for regulatory complexity, payer frameworks, and local clinical practice to optimize adoption and align evidence generation with stakeholder expectations.

Strategic corporate and laboratory approaches highlighting platform expansion, evidence partnerships, and operational scaling that drive diagnostic credibility and clinical integration

Company strategies in autoimmune diagnostics reflect divergent priorities including platform innovation, partnerships, and service expansion to capture clinical demand and laboratory preference. Leading assay developers focus on expanding assay menus and enhancing platform interoperability to meet the needs of hospital laboratories and high-volume reference centers. These efforts often pair with strategic collaborations with academic institutions to validate novel biomarkers and to generate the clinical evidence necessary for guideline inclusion and payer consideration.

Laboratory groups and diagnostics service providers invest in expanding their LDT capabilities and in establishing centers of excellence for autoimmune testing, enabling rapid deployment of new assays and supporting clinician education. At the same time, developers of multiplex technologies emphasize the value proposition of comprehensive immunoprofiling for complex autoimmune presentations, targeting neurology and rheumatology centers that require broader serologic views for differential diagnosis. Mergers, acquisitions, and co-development agreements increasingly serve as mechanisms to accelerate entry into adjacent clinical segments and to access distribution networks in key regions.

Across commercial and laboratory stakeholders, there is a shared emphasis on evidence generation, interoperability, and scalable operations. Consequently, corporate investments prioritize clinical validation studies, real-world evidence programs, and post-market surveillance that demonstrate test performance in diverse patient cohorts. This focus enables companies and laboratories to align product positioning with clinician needs, regulatory expectations, and payer requirements, reinforcing diagnostic credibility and facilitating integration into care pathways.

Actionable strategic priorities for diagnostics and laboratory leaders to strengthen evidence, enhance resilience, and accelerate clinical adoption across care pathways

Industry leaders should adopt coordinated strategies that align assay development, evidence generation, and laboratory operations to accelerate clinical adoption and improve patient outcomes. First, prioritize clinical validation programs that demonstrate actionable utility in real-world patient cohorts, ensuring that study designs reflect clinician decision points and payer evidence needs. Simultaneously, invest in interoperability and workflow integration so that assays fit seamlessly into laboratory information systems and electronic health records, thereby minimizing friction for ordering clinicians and laboratory staff.

Second, diversify supply chains and consider regional manufacturing or final assembly to reduce exposure to trade-related disruptions. Building validated dual-source options for critical reagents and components will enhance operational resilience and support sustained testing capacity. Third, develop targeted engagement plans for key end users-academic centers for translational validation, hospital laboratories for operational fit, and reference laboratories for scale. These plans should include clinician education, interpretive reporting templates, and collaborative pilot programs that demonstrate clinical value.

Fourth, pursue partnerships to expand multiplexing capabilities and to develop integrated diagnostic algorithms that combine serologic results with clinical decision support. Finally, incorporate patient-centric sampling approaches, such as dried blood spot programs, to broaden access and to support decentralized testing initiatives. By implementing these recommendations, stakeholders can strengthen their competitive positioning while delivering diagnostics that align with evolving clinical workflows and patient care models.

A transparent, multi-source research methodology combining expert interviews, guideline synthesis, and reproducible analytical frameworks to generate actionable diagnostic insights

This research synthesizes multiple data sources, structured interviews, and a transparent analytical framework to ensure robust, reproducible findings. Primary qualitative inputs include interviews with clinical laboratory directors, assay developers, regulatory affairs specialists, and clinicians who treat autoimmune diseases, providing practical insights into validation practices, adoption barriers, and clinical decision drivers. These interviews informed thematic analysis and guided the selection of case studies that illustrate real-world integration of assays into diagnostic pathways.

Secondary inputs comprised peer-reviewed literature, clinical practice guidelines, and regulatory documentation that clarify analytic requirements and evidence expectations for both in vitro diagnostics and lab-developed tests. The methodological approach balanced depth and breadth by triangulating qualitative inputs with technical performance characteristics reported in the literature, paying particular attention to assay-specific validation metrics and sample type considerations. Data synthesis emphasized reproducibility, with cross-validation steps to reconcile discrepancies across sources and to ensure that interpretive claims reflect consensus where possible.

Analytical techniques included comparative validation mapping across technologies and test types, scenario-based supply chain impact assessment, and segmentation-driven insight generation to highlight actionable priorities for developers and laboratories. Throughout, we maintained clear documentation of assumptions and methodological choices, enabling clients to evaluate the applicability of findings to specific programs or geographies.

Concluding perspective on aligning innovation, evidence generation, and operational resilience to drive meaningful improvements in autoimmune disease diagnosis

In closing, the autoimmune diagnostics field stands at an inflection point characterized by higher expectations for analytical performance, tighter alignment between evidence generation and clinical utility, and greater operational scrutiny driven by supply chain realities. Stakeholders who integrate rigorous validation, seamless workflow compatibility, and resilient procurement strategies will be best positioned to translate technological advances into tangible clinical impact. The interplay of in vitro diagnostics and lab-developed tests offers a pragmatic dual-pathway where standardization and agility coexist to meet diverse clinical needs.

Leaders should focus on generating the right kinds of evidence to satisfy clinicians and payers, while investing in interoperability and interpretive reporting to enhance clinical utility. At the same time, supply chain diversification and regional capacity planning will remain critical to ensuring continuity of testing services. Taken together, these priorities suggest a roadmap where innovation, evidence, and operations align to support earlier and more accurate diagnosis, improved patient management, and more efficient laboratory workflows. Stakeholders who act decisively to address these areas will drive adoption and deliver value to clinicians, patients, and healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of high-sensitivity anti-CCP assays to stratify rheumatoid arthritis patient risk
• 5.2. Utilization of next-generation sequencing based LDTs for personalized Sjogren syndrome diagnostics
• 5.3. Emergence of point-of-care microfluidic platforms for real-time autoimmune biomarker quantification
• 5.4. Expansion of machine learning algorithms to interpret complex autoantibody profiles in IVD workflows
• 5.5. Growth of lab-developed assays for multiplex detection of anti-dsDNA and complement proteins in SLE
• 5.6. Integration of digital immunoassays with telehealth platforms for remote monitoring of autoimmune flares
• 5.7. Regulatory harmonization efforts for standardizing clinical validation of LDTs in autoimmune disease testing
• 5.8. Implementation of CRISPR-based diagnostic tools for ultra-sensitive detection of autoimmune-related gene variants
• 5.9. Surge in use of high-throughput proteomics in IVD kits to identify novel biomarkers for autoimmune pathogenesis
• 5.10. Strategic partnerships between biotech firms and diagnostic labs to co-develop targeted autoimmune LDT panels

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. IVD & LDT For Autoimmune Diseases Market, by Test Type

• 8.1. Anti Cyclic Citrullinated Peptide
• 8.2. Antinuclear Antibody
• 8.3. Celiac Disease
• 8.4. Rheumatoid Factor

9. IVD & LDT For Autoimmune Diseases Market, by Technology

• 9.1. Chemiluminescence Immunoassay
• 9.2. Enzyme Linked Immunosorbent Assay
• 9.3. Fluorescence Immunoassay
• 9.4. Multiplex Immunoassay

10. IVD & LDT For Autoimmune Diseases Market, by Product Type

• 10.1. In Vitro Diagnostic
• 10.2. Lab Developed Test

11. IVD & LDT For Autoimmune Diseases Market, by End User

• 11.1. Academic And Research Institutes
• 11.2. Diagnostic Laboratories
• 11.3. Hospital Laboratories
• 11.4. Reference Laboratories

12. IVD & LDT For Autoimmune Diseases Market, by Application

• 12.1. Celiac Disease
• 12.2. Multiple Sclerosis
• 12.3. Rheumatoid Arthritis
• 12.4. Systemic Lupus Erythematosus
• 12.5. Type 1 Diabetes

13. IVD & LDT For Autoimmune Diseases Market, by Sample Type

• 13.1. Dried Blood Spot
• 13.2. Plasma
• 13.3. Serum
• 13.4. Whole Blood

14. IVD & LDT For Autoimmune Diseases Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. IVD & LDT For Autoimmune Diseases Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. IVD & LDT For Autoimmune Diseases Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Roche Diagnostics International AG
  • 17.3.2. Abbott Laboratories
  • 17.3.3. Thermo Fisher Scientific Inc.
  • 17.3.4. Danaher Corporation
  • 17.3.5. Siemens Healthineers AG
  • 17.3.6. bioMerieux SA
  • 17.3.7. Bio-Rad Laboratories Inc.
  • 17.3.8. DiaSorin S.p.A.
  • 17.3.9. Quidel Corporation
  • 17.3.10. EUROIMMUN AG

LIST OF FIGURES

• FIGURE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 167. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 168. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 169. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 170. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 227. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 230. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 232. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 238. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 241. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 244. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 245. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 246. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 247. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 248. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 249. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 252. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 253. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 254. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 255. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 258. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 259. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 260. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 261. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 262. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 263. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 266. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 267. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 268. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 271. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 274. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 275. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 277. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 279. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 280. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 281. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 282. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 283. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 284. ASEAN IVD & LDT